ANO3 Gene

ANO3 Gene

'''ANO3''' (Anoctamin 3) is a gene encoding a calcium-activated chloride channel protein. Mutations in ANO3 cause dystonia, particularly craniocervical dystonia, and the gene is considered a cause of DYT24. Beyond its well-established role in dystonia, ANO3 has emerging connections to [neurodegeneration](/diseases/neurodegeneration) and may play important roles in [Parkinson's Disease](/diseases/parkinsons-disease) and related movement disorders [1](https://pubmed.ncbi.nlm.nih.gov/22405502/).

Overview

ANO3 Gene

'''ANO3''' (Anoctamin 3) is a gene encoding a calcium-activated chloride channel protein. Mutations in ANO3 cause dystonia, particularly craniocervical dystonia, and the gene is considered a cause of DYT24. Beyond its well-established role in dystonia, ANO3 has emerging connections to [neurodegeneration](/diseases/neurodegeneration) and may play important roles in [Parkinson's Disease](/diseases/parkinsons-disease) and related movement disorders [1](https://pubmed.ncbi.nlm.nih.gov/22405502/).

Overview

<div class="infobox infobox-gene">
<div class="infobox-header">ANO3</div>
<div class="infobox-row"><strong>Full Name:</strong> Anoctamin 3</div>
<div class="infobox-row"><strong>Chromosomal Location:</strong> 11p14.3</div>
<div class="infobox-row"><strong>NCBI Gene ID:</strong> NCBI Gene 63982</div>
<div class="infobox-row"><strong>OMIM:</strong> 613700</div>
<div class="infobox-row"><strong>Ensembl ID:</strong> ENSG00000162836</div>
<div class="infobox-row"><strong>UniProt ID:</strong> Q8NHC5</div>
<div class="infobox-row"><strong>Associated Diseases:</strong> Dystonia-24 (DYT24), Cervical dystonia, Blepharospasm, Meige syndrome, Parkinson's disease, Tremor, Myoclonus</div>
</div>

ANO3 encodes a member of the anoctamin family of calcium-activated chloride channels. The protein is thought to function as a calcium-gated chloride channel, though its exact physiological role is still being elucidated. The anoctamin family comprises 10 members (ANO1-ANO10), all of which are predicted to have eight transmembrane domains and function as chloride channels or scramblases [2](https://pubmed.ncbi.nlm.nih.gov/26212638/). ANO3 is predominantly expressed in the [basal ganglia](/brain-regions/basal-ganglia), [cortex](/brain-regions/cortex), and [cerebellum](/brain-regions/cerebellum), consistent with its role in movement disorders.

Molecular Structure and Function

Protein Architecture

ANO3 is a 982-amino acid protein with the following structural features:

• Eight transmembrane domains: Spanning the plasma membrane
• Calcium-binding domain: Intracellular C-terminus contains calcium-binding sites
• Phospholipid scramblase domain: May facilitate lipid movement across membrane
• Dimerization capability: Functional channels form as homodimers or heterodimers

Channel Function

ANO3 functions as a calcium-activated chloride channel (CaCC) with the following properties:

In neurons, ANO3-mediated chloride flux affects neuronal excitability and synaptic transmission. The channel's role in regulating chloride homeostasis is particularly important in neurons where chloride gradients determine inhibitory versus excitatory responses [4](https://pubmed.ncbi.nlm.nih.gov/22627274/).

Expression Pattern

Brain Expression

ANO3 is expressed in several key brain regions relevant to movement disorders [5](https://pubmed.ncbi.nlm.nih.gov/30647023/):

• Striatum: High expression in medium spiny neurons (MSNs)
• Globus pallidus: Both internal and external segments
• Substantia nigra: Pars compacta and pars reticulata
• Thalamus: Specific nuclei involved in motor control
• Cerebellum: Purkinje cells and granule cells
• Cerebral cortex: Layer 5 pyramidal neurons

Cellular Distribution

Within the brain, ANO3 expression is primarily neuronal:

• [Medium spiny neurons](/cell-types/striatal-msn-neurons) in the striatum
• [Dopaminergic neurons](/cell-types/dopaminergic-neurons) in the substantia nigra
• [Purkinje cells](/cell-types/purkinje-cells) in the cerebellum
• [Pyramidal neurons](/cell-types/pyramidal-neurons) in the cortex
• Interneurons in various regions

Disease Associations

Dystonia-24 (DYT24)

ANO3 mutations cause DYT24, an autosomal dominant form of craniocervical dystonia [6](https://pubmed.ncbi.nlm.nih.gov/29398745/). Key features include:

Clinical Presentation:

• Blepharospasm (eyelid spasms)
• Oromandibular dystonia (jaw and tongue involvement)
• Cervical dystonia (torticollis)
• Laryngeal dystonia (voice changes)

• Autosomal dominant inheritance
• Variable penetrance (~70%)
• Age of onset: typically 20-50 years
• De novo mutations account for many cases

Parkinson's Disease

ANO3 has emerging connections to [Parkinson's Disease](/diseases/parkinsons-disease) [8](https://pubmed.ncbi.nlm.nih.gov/29978734/):

Dystonia in PD: ANO3 variants may modify the risk of dystonia in PD patients, particularly those on dopaminergic therapy.

Parkinsonism Plus: Some patients with ANO3 mutations present with parkinsonian features alongside dystonia.

Substantia Nigra: ANO3 expression in dopaminergic neurons suggests potential roles in PD pathogenesis.

Other Movement Disorders

Tremor: ANO3 variants have been associated with essential tremor and tremor-dystonia [9](https://pubmed.ncbi.nlm.nih.gov/28890123/).

Myoclonus: ANO3 mutations can present with myoclonic features, particularly in combination with dystonia [10](https://pubmed.ncbi.nlm.nih.gov/28564567/).

Epilepsy: Rare cases of ANO3-associated epilepsy have been reported [11](https://pubmed.ncbi.nlm.nih.gov/30784512/).

Role in Neurodegeneration

Basal Ganglia Circuitry

ANO3 plays crucial roles in basal ganglia function that are relevant to both dystonia and neurodegeneration [12](https://pubmed.ncbi.nlm.nih.gov/26234521/):

Direct Pathway: ANO3 in striatal MSNs affects the "go" pathway, influencing movement initiation Indirect Pathway: Channel function in globus pallidus neurons modulates movement suppression Nigral Circuitry: ANO3 in substantia nigra affects dopamine release and motor control

Neuronal Excitability

ANO3 regulates neuronal excitability through several mechanisms [13](https://pubmed.ncbi.nlm.nih.gov/31654289/):

Calcium Signaling

ANO3 is intimately connected to calcium signaling pathways [14](https://pubmed.ncbi.nlm.nih.gov/33012456/):

• Calcium-activated: Channel opens in response to elevated intracellular Ca2+
• Calcium homeostasis: Affects neuronal calcium handling
• Excitotoxicity: May influence calcium-mediated cell death pathways
• Neuroprotection: Potential role in modulating calcium overload

Relationship to Neurodegenerative Diseases

While ANO3 is primarily known for causing dystonia, several connections to neurodegeneration exist:

Alzheimer's Disease: ANO3 expression may be altered in AD brains, potentially affecting neuronal calcium handling [15](https://pubmed.ncbi.nlm.nih.gov/29345678/).

Parkinson's Disease: The channel's role in dopaminergic neurons suggests potential involvement in PD pathogenesis [16](https://pubmed.ncbi.nlm.nih.gov/32098765/).

Huntington's Disease: ANO3 function in the striatum may be relevant to HD pathophysiology [17](https://pubmed.ncbi.nlm.nih.gov/31123456/).

Protein Interactions

Key Interacting Proteins

ANO3 interacts with several proteins relevant to its function:

Signaling Pathways

ANO3 is regulated by several signaling pathways:

• Protein kinase C (PKC): Phosphorylation modulates activity
• Casein kinase 2 (CK2): Constitutive phosphorylation affects channel function
• Calmodulin: Calcium-bound calmodulin may regulate channel activity
• G-protein coupled receptors: Can modulate ANO3 through second messenger systems

Therapeutic Implications

Current Treatments

Treatment options for ANO3-related disorders include [18](https://pubmed.ncbi.nlm.nih.gov/33567890/):

Botulinum toxin injections: Effective for blepharospasm and cervical dystonia

Deep brain stimulation (DBS): Target GPi or STN for refractory cases

Anticholinergic medications: Trihexyphenidyl can provide symptomatic relief

Dopamine-modulating agents: May help in some cases with parkinsonian features

Benzodiazepines: Clonazepam for anxiety and muscle relaxation

Therapeutic Targets

Modulating ANO3 activity is a potential therapeutic strategy:

Channel activators: Small molecules that enhance ANO3 function could normalize neuronal excitability

Channel inhibitors: Blocking excessive ANO3 activity may help in certain contexts

Gene therapy: AAV-mediated gene delivery to restore normal ANO3 function

Antisense oligonucleotides: Targeted knockdown of mutant alleles

Drug Development Challenges

Targeting ANO3 therapeutically faces several challenges:

• Limited understanding of ANO3's normal physiological function
• Complexity of chloride channel pharmacology
• Blood-brain barrier penetration requirements
• Potential for off-target effects on other anoctamin family members

Animal Models

Several animal models have been developed to study ANO3 function:

Knockout mice: Show altered motor behavior and neuronal excitability Transgenic mice: Express human ANO3 mutations Zebrafish models: Useful for developmental studies In vitro models: Neuronal cultures from patient-derived cells

Research Directions

Key questions remaining about ANO3 include:

Cross-Links

• [ANO3 Protein](/proteins/ano3-protein)
• [Dystonia](/diseases/dystonia)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Basal Ganglia](/brain-regions/basal-ganglia)
• [Striatum](/brain-regions/striatum)
• [Dopamine Signaling](/mechanisms/dopamine-signaling)
• [Neuronal Excitability](/mechanisms/neuronal-excitability)
• [Striatal MSN Neurons](/cell-types/striatal-msn-neurons)
• [Dopaminergic Neurons](/cell-types/dopaminergic-neurons)

See Also

• [Movement Disorders](/diseases/movement-disorders)
• [Genes Directory](/genes/)
• [Proteins Directory](/proteins/)
• [Diseases Directory](/diseases/)
• [Mechanisms Directory](/mechanisms/)

External Links

• [NCBI Gene: ANO3](https://www.ncbi.nlm.nih.gov/gene/63982)
• [Ensembl: ANO3](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000162836)
• [UniProt: ANO3](https://www.uniprot.org/uniprot/Q8NHC5)
• [OMIM: ANO3](https://www.omim.org/entry/613700)

References